PO13-337 EUROACTION: A EUROPEAN SOCIETY OF CARDIOLOGY DEMONSTRATION PROJECT IN PREVENTIVE CARDIOLOGY PROGRAMME IN ASYMPTOMATIC HIGH RISK PATIENTS AND THEIR PARTNERS

2007 ◽  
Vol 8 (1) ◽  
pp. 100
Author(s):  
D. Wood ◽  
K. Kotseva ◽  
S. Connolly ◽  
C. Jennings ◽  
A. Mead ◽  
...  
Keyword(s):  
High Risk ◽  
European Society ◽  
Demonstration Project ◽  
Preventive Cardiology ◽  
High Risk Patients ◽  
Risk Patients ◽  
European Society Of Cardiology

scholarly journals Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study)

2012 ◽  
Vol 11 (4) ◽  
pp. 70-78 ◽  
Author(s):  
R. G. Oganov ◽  
V. V. Kukharchuk ◽  
G. P. Arutyunov ◽  
A. S. Galyavich ◽  
V. S. Gurevich ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Risk ◽  
European Society ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
High Risk Patients ◽  
Risk Patients ◽  
European Society Of Cardiology ◽  
Very High

The high prevalence of persistent dyslipidemia in primary and specialized care patients treated with statins justifies the need to identify its reasons and develop the recommendations on the treatment optimization. At present, Russian studies focusing on the achievement of target lipid levels remain scarce, which emphasizes the importance of the problem and its further investigation.Aim.Cross-sectional epidemiological study which assessed the prevalence of persistent dyslipidemia in statin-treated patients and analysed the predictors of the achievement of target lipid levels.Material and methods.The lipid profile parameters were analysed in 1586 statin-treated out-patients with varied levels of cardiovascular risk, taking into account the type of lipid-lowering therapy and its doses. The assessment of the cardiovascular event (CVE) risk and the definition of target levels of low-density lipoprotein cholesterol (LDL–CH), as well as normal levels of triglycerides (TG) and high-density lipoprotein cholesterol (HDL–CH), was based on the clinical recommendations by the European Society of Cardiology (ESC 2007) and by the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS 2011).Results.The analysis based on the ESC 2007 recommendations has demonstrated that the target levels of LDL–CH (<2,5 mmol/l for high-risk patients) were not achieved in 53,5% of the participants. The elevation of LDL–CH levels could be isolated or combined with the HDL–CH decrease and/or the TG increase. Low levels of HDL–CH were observed in 32,3% of the patients, while high TG levels were registered in 55,6% of the participants. The achievement of target LDL–CH levels was predicted by the higher-dose statin therapy (odds ratio 0,44). The analysis based on the ESC/EAS 2011 recommendations has shown that the prevalence of target LDL–CH levels was 12,2% in very high-risk patients (<1,8 mmol/l), 30,3% in high-risk patients (<2,5 mmol/l), and 53,4% in moderate-risk patients (<3,0 mol/l).Conclusion.Over a half of the statin-treated patients failed to achieve target levels of LDL–CH. The lowest prevalence of target LDL–CH levels was observed in very high-risk and high-risk patients. The predictors of target LDL–CH level achievement included moderate cardiovascular risk and higher-dose statin therapy. The obtained results suggest that the correction of persistent dyslipidemia in statin-treated patients could be achieved via increasing the satin dose and combining lipid-lowering medications.

scholarly journals Monitoring of biomarkers in heart failure

2019 ◽  
Vol 21 (Supplement_M) ◽  
pp. M5-M8
Author(s):  
Ilaria Spoletini ◽  
Andrew J S Coats ◽  
Michele Senni ◽  
Giuseppe M C Rosano
Keyword(s):  
Heart Failure ◽  
High Risk ◽  
Natriuretic Peptides ◽  
European Society ◽  
Consensus Meeting ◽  
High Risk Patients ◽  
Key Points ◽  
Risk Patients ◽  
European Society Of Cardiology

Abstract The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients. Beyond natriuretic peptides and troponins, the utility of novel, emerging biomarkers is less established. This document reflects the key points of a Heart Failure Association of the European Society of Cardiology (ESC) consensus meeting on biomarker monitoring in HF.

scholarly journals Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model

2016 ◽  
Vol 48 (3) ◽  
pp. 780-786 ◽  
Author(s):  
Cecilia Becattini ◽  
Giancarlo Agnelli ◽  
Mareike Lankeit ◽  
Luca Masotti ◽  
Piotr Pruszczyk ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
High Risk ◽  
Risk Stratification ◽  
Negative Predictive Value ◽  
European Society ◽  
Predictive Value ◽  
Acute Pulmonary Embolism ◽  
Risk Stratification Model ◽  
Risk Patients ◽  
European Society Of Cardiology

The European Society of Cardiology (ESC) has proposed an updated risk stratification model for death in patients with acute pulmonary embolism based on clinical scores (Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI)), right ventricle dysfunction (RVD) and elevated serum troponin (2014 ESC model).We assessed the ability of the 2014 ESC model to predict 30-day death after acute pulmonary embolism. Consecutive patients with symptomatic, confirmed pulmonary embolism included in prospective cohorts were merged in a collaborative database. Patients’ risk was classified as high (shock or hypotension), intermediate-high (RVD and elevated troponin), intermediate-low (RVD or increased troponin or none) and low (sPESI 0). Study outcomes were death and pulmonary embolism-related death at 30 days.Among 906 patients (mean±sd age 68±16, 489 females), death and pulmonary embolism-related death occurred in 7.2% and 4.1%, respectively. Death rate was 22% in “high-risk” (95% CI 14.0–29.8), 7.7% in “intermediate-high-risk” (95% CI 4.5–10.9) and 6.0% in “intermediate-low-risk” patients (95% CI 3.4–8.6). One of the 196 “low-risk” patients died (0.5%, 95% CI 0–1.0; negative predictive value 99.5%).By using the 2014 ESC model, RVD or troponin tests would be avoided in about 20% of patients (sPESI 0), preserving a high negative predictive value. Risk stratification in patients at intermediate risk requires further improvement.

EUROACTION: An ESC project in preventive cardiology programme in coronary and high risk patients and their partners

2007 ◽  
Vol 194 (1) ◽  
pp. 285 ◽  
Author(s):  
K. Kotseva ◽  
S.B. Connolly ◽  
C. Jennings ◽  
A. Mead ◽  
J. Jones ◽  
...  
Keyword(s):  
High Risk ◽  
Preventive Cardiology ◽  
High Risk Patients ◽  
Risk Patients

Prevalence and Risk Distribution of Residual Dyslipidemia in Statin-Treated Patients in Greece

Angiology ◽  
2011 ◽  
Vol 63 (3) ◽  
pp. 184-193 ◽  
Author(s):  
Evangelos Liberopoulos ◽  
Fotini Vlasserou ◽  
Zoe Mitrogianni ◽  
Ioannis Papageorgantas ◽  
Moses Elisaf
Keyword(s):  
High Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lipid Management ◽  
High Risk Patients ◽  
Low Hdl ◽  
Risk Patients ◽  
Cv Disease ◽  
European Society Of Cardiology

Many statin-treated patients are not achieving treatment goals and are at risk of cardiovascular (CV) disease. We report the results of patients enrolled in an observational study in Greece, which estimated the residual lipid abnormalities in statin-treated patients. Low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglyceride concentrations were recorded in patients receiving statin therapy for ≥3 months, classified by CV risk according to European Society of Cardiology guidelines. Sixty-three percent of statin-treated patients had an LDL-c not at goal. Low-risk patients were more likely to have an LDL-c not at goal compared with high-risk patients (67.3% vs 61.0%, respectively). They were also less likely to have low HDL-c levels and elevated triglyceride levels compared with high-risk patients. Smoking and sedentary lifestyle were not associated with dyslipidemia in this population. Approximately two thirds of statin-treated patients in Greece are not reaching target/normal lipid levels and could benefit from improved lipid management.

scholarly journals Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis

Heart ◽  
2018 ◽  
pp. heartjnl-2018-313700 ◽  
Author(s):  
Constantinos O’Mahony ◽  
Mohammed Majid Akhtar ◽  
Zacharias Anastasiou ◽  
Oliver P Guttmann ◽  
Pieter A Vriesendorp ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hypertrophic Cardiomyopathy ◽  
High Risk ◽  
Sudden Cardiac Death ◽  
European Society ◽  
Cardiac Death ◽  
Meta Analysis ◽  
Registration Number ◽  
Risk Patients ◽  
European Society Of Cardiology

ObjectiveIn 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%–<6% and ≥6%, respectively).MethodsThe protocol was registered with PROSPERO (registration number: CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model.ResultsSix (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients.ConclusionsThis meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines.Registration numberPROSPERO CRD42017064203;Pre-results.

Sign in / Sign up

Export Citation Format

Share Document